BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-701@pharmaconomics
DTSTAMP:20260707T015339Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:URGN Phase 1 — UGN-501 (estimated date)
DESCRIPTION:Phase 1 trial results for UGN-501 in high-grade non-muscle invasive bladder cancer (HG-NMIBC) are due ~ Dec 31\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/ex_956006.htm\n\nTrack it: https://pharmaconomics.com/e/701
URL:https://pharmaconomics.com/e/701
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:URGN catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR